Can a new eyedrop calm the redness and goo of infectious pink eye?
NCT ID NCT05636228
First seen Sep 18, 2026 · Last updated Sep 18, 2026
Summary
Researchers are testing an experimental eyedrop called INV-102 in adults with acute infectious keratoconjunctivitis, a common eye infection that causes redness and discharge. The Phase 2 trial randomly assigns participants to receive either INV-102 or a vehicle drop for one week, with a follow-up visit a week later. The main goal is to see whether INV-102 reduces a combined score of eye redness and discharge better than the vehicle. A secondary goal is to track how many participants need additional rescue therapy.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- INV-102 ophthalmic solution, an experimental eyedrop
- What this could lead to
- If it works, INV-102 could offer a fast-acting eyedrop that eases redness and discharge from infectious pink eye without waiting for the infection to clear on its own.
- What could go wrong
- This is a mid-stage trial with 93 participants, so it may not show a clear benefit over the vehicle drop. Eyedrops can cause stinging, irritation, or allergic reactions, and results in a small group may not hold up in larger studies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
93 people
The number who actually took part.
- Started
-
Jun 2023
- Finished
-
Aug 2024
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Male or female patient ≥ 18 years of age * A clinical diagnosis of AIK with a minimum of a 2+ (moderate) conjunctival hyperemia and a minimum of 1+ (mild) discharge (whether it be watery or purulent) in at least one eye Exclusion Criteria: * Untreated keratoconjunctivitis of any type that has lasted 96 consecutive hours or more prior to baseline visit * Infectious blepharitis as the primary cause of ocular hyperemia and discharge in the opinion of the investigator (Note: If the blepharitis is secondary to the conjunctivitis, the patient can be included) * Suspected allergic conjunctivitis as a primary cause of conjunctival hyperemia (bulbar redness) and/or discharge in the opinion of the Investigator * Suspected corneal ulcer * Ocular topical steroid use within two weeks prior to baseline visit * Ocular topical antibiotic use for less than 24 hours or greater than 96 hours of dosing prior to Baseline visit (this does NOT exclude naïve patients or patients that have not taken topical antibiotics) * Ocular topical povidone iodine use within 1 week prior to baseline visit * Systemic antibiotic use within 2 weeks prior to baseline visit * Ocular topical or systemic anti-fungal within 2 weeks prior to baseline visit * Ocular topical or systemic anti-viral use within 2 weeks prior to baseline visit * Corticosteroid (including but not limited to oral, intranasal, inhaled, topical, etc.) or any immunosuppressant use within 30 days prior to Baseline visit * On current treatment for herpes keratitis (evidence of herpes keratitis and/or ocular dendrites can be included) * Known or suspected ocular fungal infection or ocular microsporidia infection
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Acute infectious keratoconjunctivitis are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Athens Eye Care
Athens, Ohio, 45701, United States
-
D & H National Research Centers, INC
Miami, Florida, 33155, United States
-
Foothill Eye Institute
Pasadena, California, 91107, United States
-
Global Research Management
Glendale, California, 91204, United States
-
Kannarr Eye Center
Pittsburg, Kansas, 66762, United States
-
King Chulalongkorn Memorial Hospital
Bangkok, 10330, Thailand
-
Mahidol university
Bangkok, 10400, Thailand
-
My Community Research Center, Inc.
Miami, Florida, 33155, United States
-
Oculos Clinical Research
Garner, North Carolina, 27529, United States
-
Quantum Clinical Trials
Miami Beach, Florida, 33140, United States
-
Revolution Research/ Lake Travis Eye and Laser Center
Lakeway, Texas, 78738, United States
-
Shettle Eye Research
Largo, Florida, 33773, United States